From The Motley Fool · Motley Fool Transcribing · · 2m
Kamada Q3 2026 Earnings Report
Kamada boosts Q3 revenue by 11% with KEDRAB market share at 50% in U.S.
In brief
Kamada boosts Q3 revenue by 11% with KEDRAB market share at 50% in U.S. Kamada reported $52 million Q3 revenue, 11% YoY growth, and $15.2 million adjusted EBITDA with 29% margin. Originally reported by The Motley Fool.
Q3 Revenue
Total revenue reached $52 million for the third quarter, increasing 11% year over year.
Adjusted EBITDA
Adjusted EBITDA stood at $15.2 million, a 30% year over year increase with 29% margin.
Net Income
Net income totaled $8 million for the quarter, representing 51% year over year growth.
2026 Revenue Guidance
2026 revenue guidance increased to $205 million to $208 million from previous range of $200 million to $205 million.
Distribution Segment
Distribution segment revenue reached $24.1 million for first nine months, a 35% year over year increase.
KEDRAB Market Share
KEDRAB holds at least 50% market share in U.S. supported by CDC health advisory.
Plasma Supply Agreement
Plasma supply agreement worth $50 million over three years to supply normal source plasma.
Biosimilar Revenue Guidance
Biosimilar revenue expected to reach $10 million annually by 2028 and $20 million to $25 million by 2030.
Dividend Payments
Dividend payments totaled $32.3 million for 2026, including $0.14 per share for Q4.
Gross Margins
Gross margins increased to 45% for Q3, up from 42% last year due to improved product mix.
Operating Expenses
Operating expenses rose to $13 million in Q3, up from $11.9 million due to expanded commercial operations.
Nine-Month Net Income
Nine-month net income reached $21.4 million, a 29% year over year increase.
Nine-Month Adjusted EBITDA
Nine-month adjusted EBITDA totaled $40.9 million, a 20% year over year increase with 27% margin.
Nine-Month Revenue
Nine-month revenue reached $152.2 million, a 12% year over year increase driven by KEDRAB, VARIZIG, and HEPAGAM B.
2027 Financial Projections
Management projects double-digit growth for both revenues and profitability in 2027.
Biosimilar Pipeline
At least two additional biosimilar products scheduled for commercial launch in Israeli market next year.
The one thing
Kamada reported $52 million Q3 revenue, 11% YoY growth, and $15.2 million adjusted EBITDA with 29% margin.
